Drug intelligence / Profile preview

FK50

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Oral, Intramuscular

Overview

FK50, specifically referred to as MAb FK50-4 in research, is a monoclonal antibody developed to neutralize Feline Infectious Peritonitis Virus (FIPV). It targets and recognizes the FIPV small integral membrane glycoprotein, known as M protein. This antibody demonstrates a unique property by exhibiting strong neutralizing activity in feline macrophages, even after the virus has absorbed into the cells, but not in other cell lines like CrFK or fcwf-4 cells. This suggests a cell-tropism dependent mechanism of action.

Other names: MAb FK50-4

Targets

FIPV M protein (Feline infectious peritonitis virus membrane glycoprotein)

Beyond the preview

Go deeper on FK50.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FK50.

Explore the full profile